AMRN

EX-99.1

2 amrn-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income

DUBLIN, Ireland and BRIDGEWATER, N.J., October 28, 2026 -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued U.S. market share leadership.

Delivering On Our Performance Objectives

“Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA®/VAZKEPA® (icosapent ethyl, or IPE) franchise and deliver long-term shareholder value,” said Aaron Berg, President & Chief Executive Officer. “International in-market demand grew at a double-digit pace across our partner network reflecting increased adoption by patients and prescribers, and we maintained leadership in the U.S. IPE market amid pricing pressure from generic competition.”

($ in millions)

Q4 2025

Q1 2026

Q2 2026

Q3 2026

FY 2026 Expectations

Operating Expense Reduction from Prior Year Period, Excluding Restructuring Charges

(41)%

(38)%

(38)%

(22)%

Further reductions in Q4

Net Cash Provided by Operating Activities

$7.0

$6.4

$6.6

$9.2

Positive for Q4

Cash, Cash Equivalents & Short-Term Investments

$302.6

$307.8

$314.6

$323.4

~$330

Inventory

$195.9

$183.6

$164.1

$158.9

Maintain disciplined approach that aligns with demand and reflects improved contracting

Debt

$0

$0

$0

$0

Remain debt free

Global Commercial Momentum and Continued U.S. Market Leadership

• In Europe, in-market demand for VAZKEPA increased by an estimated 68% in Q3 2026 compared with Q3 2025, reflecting strong execution and increased investment by Recordati S.p.A. (“Recordati”) under our exclusive license and supply agreement. Momentum was driven by strong performance in Spain, the UK and Italy. Growth in Europe significantly exceeded the historical European growth rates achieved by Amarin before the partnership began in Q2 2025.

• As of September 30, 2026, VASCEPA/VAZKEPA was commercially available in 22 countries worldwide, including 11 European countries through Recordati. The Recordati agreement covers 59 countries with patent protection for VASCEPA / VAZKEPA extending through 2039 in these markets.

• VAZKEPA was launched into the private pay market in Poland (non-reimbursed) during the month of October. Recordati is currently advancing pricing, reimbursement and market access activities to support planned

launches in additional licensed markets. These launches, when completed, are expected to increase the number of countries where VAZKEPA will be commercially available.

• Across our global partner network, in-market demand for VASCEPA/VAZKEPA increased by an estimated 55% in Q3 2026 compared with Q3 2025.

• In the United States, the Company’s leading share of the IPE market was 47% in Q3 2026, reinforcing the power of VASCEPA’s clinical differentiation, the trust of prescribers and patients, our proven ability to reliably supply the market and the disciplined execution of our commercial team.

• The Company expects U.S. volumes to remain broadly stable for the remainder of FY 2026.

Financial Highlights

($ in millions)

Q3

2026

Q3

2025

% Change

9 Mos. 2026

9 Mos. 2025

% Change

Total Net Revenue

$39.6

$49.7

(20)%

$126.9

$164.4

(23)%

Operating Expenses

$18.5

$33.3

(44)%

$74.6

$141.5

(47)%

Operating Loss

$(2.4)

$(11.1)

79%

$(25.7)

$(43.8)

41%

Operating Margin %*

(6)%

(22)%

16 pts

(20)%

(27)%

7 pts

Net Loss

$0.2

$(7.7)

103%

$(17.9)

$(37.6)

52%

Net Margin

1%

(16)%

16 pts

(14)%

(23)%

9 pts

*Operating margin is calculated as operating loss divided by total net revenue

Peter Fishman, Amarin’s Chief Financial Officer, said, “We reported our first profitable quarter in over two years, reflecting our lower expense base and the absence of charges following the completion of our previously announced $70 million cost savings initiatives. We generated positive free cash flow for the fourth consecutive quarter. Our cash balance now exceeds $323 million and our balance sheet remains debt-free.”

He continued, “We are encouraged by the in-market demand growth for VASCEPA/VAZKEPA across Europe and the rest of the world, reflecting its expanding market presence. We expect this growth to support increased partner supply purchases and related revenue over time as our partner-led sales model matures. The timing and level of product revenue will continue to reflect factors outside our direct control, including partner inventory levels, ordering patterns, as well as market access and pricing. In the U.S., we have efficien

EX-99.1

2 amrn-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow

For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA’s U.S. Market Share, an Improved OPEX Profile, and Positive Cash Flow Generation

DUBLIN, Ireland and BRIDGEWATER, N.J., July 29, 2026 -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the second quarter ended June 30, 2026 (Q2 2026) and highlighted positive outlooks associated with the one-year anniversary of its fully partnered international commercial strategy.

In June 2025, Amarin entered into an exclusive long-term license and supply agreement with Recordati S.p.A. (“Recordati”) to commercialize VASCEPA®/VAZKEPA® (icosapent ethyl or IPE) across 59 countries focused in Europe. This transformational agreement enabled Amarin to significantly reduce its operating expenses while simultaneously expanding VAZKEPA’s presence in one of the world's largest cardiovascular pharmaceutical markets, where cardiovascular disease affects an estimated 62 million people and carries an annual economic burden of approximately €282 billion across the European Union.i While commercialization remains in the early stages, Recordati has made progress advancing pricing, reimbursement, market access and adoption across the licensed territory.

“The strategic actions we have taken are driving stronger results and a path to sustained growth and profitability,” said Aaron Berg, President and Chief Executive Officer. “Amarin’s results for Q2 2026 demonstrated a positive early international sales trajectory as in-market demand increased 59% year over year across our global partner network. Operating expenses, excluding restructuring charges, declined by $16.6 million, or 38% compared to Q2 2025, in line with the previously announced $70 million annual cost savings initiative that we have now completed. We also maintained our leading U.S. IPE sales presence for VASCEPA. We are confident in the significant opportunities that lie ahead to improve patient outcomes, and continue to work closely with Barclays, our exclusive financial advisor, to explore additional potential pathways to further enhance shareholder value."

Select Operational Highlights and Outlook

• Across our global partner network, in-market demand for VASCEPA/VAZKEPA rose by 59% in Q2 2026 compared to Q2 2025, including 90% year-to-date growth in in-market volume in China versus the same period last year.

• In-market demand in Europe for VAZKEPA rose by 69% in Q2 2026 from Q2 2025.

• As of June 30, 2026, VASCEPA / VAZKEPA was commercially available in 22 countries across the globe.

• As of June 30, 2026, VAZKEPA is commercialized in 11 countries in Europe, with pricing, reimbursement, market access and adoption continuing to build across additional countries within Recordati’s licensed territory.

• The Company continues to work closely with our partners to advance regulatory submissions and support partners' needs through various stages of review and market launch preparations. Momentum remains strong

across Europe and Asia, with Singapore and South Korea progressing toward anticipated near-term commercialization.

• The Company’s share of the U.S. IPE market increased to 48% in Q2 2026 compared to 43% in Q2 2025. VASCEPA branded prescriptions rose by 14% from Q2 2025.

• The Company expects that U.S. volumes will remain consistent throughout FY 2026.

Select Financial Highlights and Outlook

• Operating expenses declined by $39.3 million, or 59% compared to Q2 2025, in line with the previously announced and now completed $70 million annual cost savings initiative. Excluding restructuring charges incurred in Q2 2025, operating expenses declined by $16.6 million, or 38%, in line with the previously announced and now completed $70 million annual cost savings initiative.

• Inventories as of June 30, 2026 declined by $19.5 million from March 31, 2026 and by $31.8 million from December 31, 2025.

• Cash as of June 30, 2026 was $314.6 million, compared to $302.6 million at December 31, 2025. The Company expects cash to grow by approximately 10% as of December 31, 2026 compared to December 31, 2025.

• The Company remained debt free as of June 30, 2026.

Financial Highlights

($ in millions)

Q2 2026

Q2 2025

% Change

1H 2026

1H 2025

% Change

Total Net Revenue

$42.2

$72.7

(42)%

$87.3

$114.8

(24)%

Operating Expenses

$27.0

$66.3

(59)%

$56.1

$108.2

(48)%

Operating Loss

$(12.0)

$(16.0)

25%

$(23.3)

$(32.7)

29%

Operating Margin %*

(28)%

(22)%

(6) pts

(27)%

(29)%

2 pts

Net Loss

$(7.7)

$(14.1)

46%

$(18

EX-99.1

2 amrn-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Amarin Reports 2026 First Quarter Financial Results

Total Revenue Increased Led by Higher International Sales

Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow

Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management

DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the first quarter ended March 31, 2026 (Q1 2026).

“Our results for Q1 2026 reflected the early yet measurable progress generated by our refined global business model which we adopted in mid-2025,” said Aaron Berg, President and Chief Executive Officer.

“The promise of our fully-partnered international commercial strategy – anchored by our European-focused exclusive licensing and supply agreement with Recordati S.p.A. (Recordati) - was reflected in higher European product revenue in Q1 2026 compared to Q4 2025. This consecutive quarterly growth was attributable to strong in-market demand for VAZKEPA® (icosapent ethyl) and the priority assigned by Recordati to expand the commercial reach for this proven therapy. While acknowledging that European sales will vary quarter to quarter, especially in the early days of this new partnership, these initial results are encouraging. Recordati has commenced commercial efforts of VAZKEPA in 10 countries, including a Q4 2025 launch in Italy, and plans to expand its distribution across Europe over the next several years. We are also seeing good growth from our active commercial partners outside of Europe.

“Our U.S. franchise continues to demonstrate remarkable resilience, where we have maintained our leading market share for VASCEPA® more than five years since the introduction of generics. Industry prescription data for Q1 2026 showed an overall increase in the icosapent ethyl (IPE) market while VASCEPA-branded prescriptions rose by 17% compared to Q1 2025. We expect that volumes will remain stable throughout 2026. Our streamlined U.S. operation remains an efficient, cash generating engine for our Company.”

He continued, “We are encouraged by the 2026 American College of Cardiology (ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline Update from March of this year that supports the broader clinical role of IPE in reducing cardiovascular (CV) risk in statin-treated patients with elevated triglycerides. These guidelines shift CV care toward early, lifelong prevention and a more comprehensive risk approach beyond just lowering LDL cholesterol. In recognizing that high triglyceride levels contribute to CV events in many patients, this framework underscores the need for additional therapies beyond statins to address this care gap. This evolutionary perspective on CV risk management is timely and strengthens our position to address the burden of CV disease in patients and across the healthcare ecosystem.”

Mr. Berg concluded, “We have created a new version of Amarin – focused, leaner, and both financially and operationally stronger than at any time in our recent history. The growth initiatives we have undertaken and building industry tailwinds increasingly focused on the needs of patients with elevated triglycerides have positioned us well

for 2026. Our team is executing with focus and discipline to achieve our objectives and deliver shareholder value, while continuing to work closely with Barclay’s, our exclusive financial advisor, in exploring additional potential pathways to further enhance shareholder value. While there is still work to be done, we look forward to our future with confidence.”

Q1 2026 Financial Highlights

($ in millions)

Q1 2026

Q1 2025

% Change

Total Net Revenue

$45.1

$42.0

7%

Operating Expenses

$29.1

$41.9

(31)%

Operating Loss

$(11.3)

$(16.8)

(32)%

Operating Margin %*

(25)%

(40)%

NM

Net Loss

$(10.5)

$(15.7)

33%

Net Margin

(23)%

(37)%

NM

Cash

$307.8

$281.8

*Operating margin is calculated as operating loss divided by total net revenue

NM – Not Meaningful

Peter Fishman, Amarin’s Chief Financial Officer, said, “We are encouraged by our Q1 2026 performance under our new business model. We achieved higher total revenue, led by growth from our partners, and a continued decline in our operating expenses, both of which led to significantly narrowed losses compared to the same period last year. We remain on track to realize the approximately $70 million in cost savings and have incurred nearly all of the associated restructuring costs. Finally, we generated positive cash flow for the second consecutive quarter and continue to expect to be cash flow positive for full year 2026.”

Q1 2026 Financial Performance

Comparisons to Q1 2025, unless otherwise sta